BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 7622930)

  • 1. Clinical features and diagnosis of relapses in leprosy.
    Ramu G
    Indian J Lepr; 1995; 67(1):45-59. PubMed ID: 7622930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New lesions after MDT in PB and MB leprosy: a report of 28 cases.
    Kar HK; Sharma P
    Indian J Lepr; 2008; 80(3):247-55. PubMed ID: 19432355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relapses among leprosy patients treated with multidrug therapy: experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia; practical difficulties with diagnosing relapses; operational procedures and criteria for diagnosing relapses.
    Becx-Bleumink M
    Int J Lepr Other Mycobact Dis; 1992 Sep; 60(3):421-35. PubMed ID: 1474281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relapses in leprosy patients after release from dapsone monotherapy; experience in the leprosy control program of the all Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia.
    Becx-Bleumink M
    Int J Lepr Other Mycobact Dis; 1992 Jun; 60(2):161-72. PubMed ID: 1522358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study on trend of relapse in leprosy and factors influencing relapse.
    Ali MK; Thorat DM; Subramanian M; Parthasarathy G; Selvaraj U; Prabhakar V
    Indian J Lepr; 2005; 77(2):105-15. PubMed ID: 16044808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in the size and number of skin lesions in PB leprosy on treatment and follow-up.
    Rao PN; Suneetha S; Pratap DV
    Lepr Rev; 2011 Sep; 82(3):244-52. PubMed ID: 22125932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Why relapse occurs in PB leprosy patients after adequate MDT despite they are Mitsuda reactive: lessons form Convit's experiment on bacteria-clearing capacity of lepromin-induced granuloma.
    Chaudhuri S; Hajra SK; Mukherjee A; Saha B; Mazumder B; Chattapadhya D; Saha K
    Int J Lepr Other Mycobact Dis; 1998 Jun; 66(2):182-9. PubMed ID: 9728450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A study on the effectiveness and safety of the WHO/MDT regimen in the northeast of Thailand; a prospective study, 1984-1996.
    Dasananjali K; Schreuder PA; Pirayavaraporn C
    Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):28-36. PubMed ID: 9207751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A study on the impact of FD-MDT on 200 leprosy patients.
    Vara N; Marfatiya Y
    Indian J Lepr; 2005; 77(3):217-27. PubMed ID: 16353520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of relapse in leprosy after fixed-duration multidrug therapy.
    Li HY; Hu LF; Huang WB; Liu GC; Yuan LC; Jin Z; Li X; Li JL; Yang ZM
    Int J Lepr Other Mycobact Dis; 1997 Jun; 65(2):238-45. PubMed ID: 9251597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical, histopathological and bacteriological study of 52 referral MB cases relapsing after MDT.
    Shetty VP; Wakade AV; Ghate SD; Pai VV; Ganapati RR; Antia NH
    Lepr Rev; 2005 Sep; 76(3):241-52. PubMed ID: 16248211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies on risk of leprosy relapses in China: relapses after treatment with multidrug therapy.
    Chen XS; Li WZ; Jiang C; Ye GY
    Int J Lepr Other Mycobact Dis; 1999 Dec; 67(4):379-87. PubMed ID: 10700911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multidrug therapy in leprosy can prevent relapse--a retrospective study.
    Biswas S; Mondal KK
    Indian J Lepr; 2002; 74(4):313-8. PubMed ID: 12624979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does concomitant hiv infection has any epidemiological, clinical, immunopathological and therapeutic relevance in leprosy?
    Kar HK; Sharma P
    Indian J Lepr; 2007; 79(1):45-60. PubMed ID: 17578267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined 12-month WHO/MDT MB regimen and Mycobacterium w. vaccine in multibacillary leprosy: a follow-up of 136 patients.
    Kaur I; Dogra S; Kumar B; Radotra BD
    Int J Lepr Other Mycobact Dis; 2002 Sep; 70(3):174-81. PubMed ID: 12483965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term follow up of patients with multibacillary leprosy and HIV infection.
    Jacob M; George S; Pulimood S; Nathan N
    Int J Lepr Other Mycobact Dis; 1996 Dec; 64(4):392-5. PubMed ID: 9030104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leprosy beyond MDT: study of follow-up of 100 released from treatment cases.
    Vara N; Agrawal M; Marfatia Y
    Indian J Lepr; 2010; 82(4):189-94. PubMed ID: 21434595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of ML dipstick as a tool to classify leprosy patients.
    Buhrer-Sekula S; Sarno EN; Oskam L; Koop S; Wichers I; Nery JA; Vieira LM; de Matos HJ; Faber WR; Klatser PR
    Int J Lepr Other Mycobact Dis; 2000 Dec; 68(4):456-63. PubMed ID: 11332289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of relapse in leprosy. The Leprosy Unit, WHO.
    Indian J Lepr; 1995; 67(1):13-26. PubMed ID: 7622926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fixed-duration multidrug therapy in multibacillary leprosy.
    Li HY; Hu LF; Wu PW; Luo JS; Liu XM
    Int J Lepr Other Mycobact Dis; 1997 Jun; 65(2):230-7. PubMed ID: 9251596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.